PBSC collection from family donors in Japan: A prospective survey

Bone Marrow Transplantation

Volumn 49, Issue 2, 2014, Pages 195-200

  Kodera, Y ^a   Yamamoto, K ^b   Harada, M ^c   Morishima, Y ^a   Dohy, H ^d   Asano, S ^e   Ikeda, Y ^e   Nakahata, T ^f   Imamura, M ^g   Kawa, K ^h   Kato, S ⁱ   Tanimoto, M ^j   Kanda, Y ^k   Tanosaki, R ^l   Shiobara, S ^m   Kim, S W ^l   Nagafuji, K ⁿ   Hino, M ^o   Miyamura, K ^p   Suzuki, R ^q   Hamajima, N ^q   Fukushima, M ^r   Tamakoshi, A ^a   Halter, J ^s   Schmitz, N ^t   Niederwieser, D ^u   Gratwohl, A ^v   more..

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^e WASEDA UNIVERSITY   (Japan)

^f KYOTO UNIVERSITY   (Japan)

^g HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^h RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

ⁱ TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^k JICHI MEDICAL UNIVERSITY   (Japan)

^l NATIONAL CANCER CENTER HOSPITAL   (Japan)

^m Japan Red Cross Ishikawa Blood Ctr   (Japan)

ⁿ KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^o OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^p JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^q NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^r Foundation for Biomedical Research and Innovation   (Japan)

^s UNIVERSITY HOSPITAL BASEL   (Switzerland)

^t UNIVERSITY OF KIEL   (Germany)

^u UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^v UNIVERSITY OF BASEL   (Switzerland)

more..

Author keywords

Acute adverse events; Family donors; Late health problems; PBSC harvest (PBSCH); Predictive factors; Prospective study

Indexed keywords

COHORT STUDIES; FEMALE; HUMANS; JAPAN; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84893798068     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.147     Document Type: Article

References (41)

1. Russell NH, Hunter A, Rogers S, Hanley J, Anderson D. Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet 1993; 341: 1482.
2. Dreger P, Suttorp M, Haferlach T, Loffler H, Schmitz N, Schroyens W. Allogeneic granulocyte colony stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood 1993; 81: 1404-1407.
3. Weaver CH, Buckner CD, Longin K, Appelbaum FR, Rowley S, Lilleby K et al. Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood 1993; 82: 1981-1984.
4. Tanaka J, Imamura M, Zhu X, Kobayashi S, Imai K, Hashino S et al. Potential benefit of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood stem cells for allogeneic transplantation. Blood 1994; 84: 3595-3596.
5. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
6. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR et al. Blood and Marrow Clinical Trials Network. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367: 1487-1496.
7. Schmitz N, Dreger P, Suttorp M, Suttorp M, Rohwedder EB, Harferlach T et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by Filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
8. Schmitz N, Bacigalupo A, Hansenclever D, Nagler A, Gluckman E, Clark P et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 995-1003.
9. Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomized trial. Lancet 2000; 355: 1231-1237.
10. Friedrichs B, Tichelli A, Bacigalupo A, Russellet NH, Ruutu T, Shapira MY et al. Long-term outcome and late effects in patients transplanted with mobilized blood or bone marrow: a randomized trial. Lancet Oncol 2010; 11: 331-338.
11. Anderlini P, Korbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997; 90: 903-908.
12. Confer DL, Stroncek DF. Bone marrow and peripheral blood stem cell donors-Thomas ED, Blume KG, Forman SJ (eds)In Hematopoietic Cell Transplantation. Blackwell Science, Inc: MA, USA 421-430, 1999.
13. Baker D, Durrant S. Fatal stroke following filgrastim mobilization of PBPC for allogeneic transplantation. Bone Marrow Transplant 1999; 23(Suppl 1): s236.
14. Adler BK, Salzman DE, Carabasl MH, Vaughan WP, Reddy VVB, Prchal JT. Fetal sickle cell crisis after granulocyte colony-stimulating factor administratio. Blood 2001; 97: 3313-3314.
15. de Azevedo AM, Tabak DG. Life-threatening capillary leak syndrome after G-CSF mobilization and collection of peripheral blood progenitor cells for allogeneic transplantation. Bone Marrow Transplant 2001; 28: 311-312.
16. Becker PS, Wagle M, Matous S, Swanson RS, Piban G, Lowry PA et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): Occurrence in allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant 1997; 3: 45-49.
17. Falzetti F, Aversa F, Minelli O, Tabilio A. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 1999; 353: 555.
18. Halter JP, van Walraven SM, Worel N, Bengtsson M, Hagglund H, Nicoloso de Faveri G et al. Allogeneic hematopoietic stem cell donation: standardized assessment of donor outcome data. A WBMT consensus document. Bone Marrow Transplant. (advance online publication) 2012; 48: 220-225.
19. Halter JP, Kodera Y, Ispizua AU, Ispizua U, Greinix HT, Schmitz N et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009; 94: 94-101.
20. Makita K, Ohta K, Mugitani A, Hagihara K, Ohta T, Yamane T et al. Acute myelogeneous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplant 2004; 33: 661-665.
21. Sakamaki S, Takamoto S, Shibata H. Complications of marrow harvesting for transplantation. Jpn J Clin Hematol 1994; 35: 29-35in Japanese.
22. Murata M, Harada M, Kato S, Takahashi S, Ogawa H, Okamoto S et al. Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors. Bone Marrow Transplant 1999; 24: 1065-1071.
23. Cleaver SA, Goldman JM. Use of G-CSF to mobilize PBSC in normal healthy donorsan international survey. Bone Marrow Transplant 1998; 21(Suppl 3): s29-s31.
24. Anderlini P, Przepiorka D, Seong D, Miller P, Sundberg J, Lichtiger B et al. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of changes for the procedures. Transfusion 1996; 36: 590-595
25. Hasenclever D, Sextro M. Safety of AlloPBSCT donors: Biochemical considerations on monitoring long term risks. Bone Marrow Transplant 1996; 17(Suppl 2): s28-s31.
26. De la Rubia J, de Arriba F, Arbona C, Pascual MJ, Zamora C, Insunza A et al. Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica 2008; 93: 735-740.
27. Cavallaro AM, Lilleby K, Majolino I, Storb R, Appelbaum FR, Rowley SD et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000; 25: 85-89.
28. Canales MA, Arrieta R, Gomez-Rioja R, Diez J, Jimenez-Yuste V, Hernandez-Navarro F. Induction of a hypercoagulability state and endotherial cell activation by granulocyte colony-stimulating factor in peripheral blood stem cell donors. J Hematother Stem Cell Res 2002; 11: 675-681.
29. Topcuoglu P, Arat M, Dalva K, Ozcan M. Administration of granulocyte-colonystimulating factor for allogeneic hematopoietic cell collection may induce the tissue factor-dependent pathway in healthy donors. Bone Marrow Transplant 2004; 33: 171-175.
30. Karadogan C, Karadogan I, Bilgin AU, Under L. rHuG-CSF increases the plateletneutrophil complex formation and neutrophil adhesion molecule expression in volunteer granulocyte and stem cell apheresis donors. Apher Dial 2006; 10: 180-186.
31. Nagler A, Korenstein-Ilan A, Amiel A, Avini L. Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 2004; 32: 122-130.
32. Hirsch B, Oseth L, Cain M, Trader E, Pulkrabek S, Lindgren B et al. Effects of granulocyte-colony stimulating factor on chromosome aneuploidy and replication asynchrony in healthy peripheral blood stem cell donors. Blood 2011; 118: 2602-2608.
33. Avalos BR, Lazaryan A, Copelan EA. Can G-CSF cause leukemia in hematopoietic stem cell donors? Biol Blood Marrow Transplant 2011; 17: 1739-1746.
34. Anderlini P, Przepiorka D, Champlin R, Korbling M. Biological and clinical effects of granulocyte colony stimulating factor in normal individuals. Blood 1996; 88: 2819-2825.
35. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007-2011.
36. Margolis D, Dincer A, Anderson L, Moraski L, Casper J, Gottshall J. Serious adverse events in peripheral blood progenitor cell mobilization: A trigger for changing the donation process. Blood 2001; 98: 178a.
37. World Health Organization. WHO guiding principles on human cells, tissue and organ transplantation. Transplantation 2010; 90: 229-233.
38. Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD et al. Adverse events among 2408 unrelated donors of peripheral blood stem cell: results of a prospective trial from National Marrow Donor Program. Blood 2009; 113: 3604-3611.
39. Holing K, Kramer M, Kroschinsky F, Bornhauser M, Menbling T, Schmidt AH et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3929 donors. Blood 2009; 114: 3757-3763.
40. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the research on adverse drug events and reports (RADAR) project. Br J Haematol 2006; 135: 642-650.
41. Pentz RD. Healthy sibling donation of G-CSF primed stem cells: Call for research. Pediatr Blood Cancer 2006; 46: 407-408.